Posts Tagged StockAnalysis

Stock Analysis: Poly Medicure

Poly Medicure is a leading supplier of Intravenous (IV) Cannulae, Safety IV Cannuale, IV infusion sets and blood bags. Safety IV devices itself is globally a $300-350 Mn annual market size today. (This was a 20 year patent granted to Braun in 1999, so is valid till 2018).

They manufacture around 95 products.

Subsidiaries in China and US. Egypt is a joint venture. China has been a major factor in reduction of raw materials.

Major RM is plastics, which is dependent on crude oil. Custom duty on medical and life saving equipment reduced by the Govt. in Feb’13 budget.

Revenue growth of 25% (approx.) and NPM of 12-13% from the past 3-4 years. See no reason why the revenue increase won’t continue at about 20% and NPMs sustain at 12-13% for the next 2-3 years. Forex derivative contracts expired in Oct 2012. Now, only simple forward hedging.

B Braun, BD, Hospitec, J&J, 3M and Poly Medicure are among the main players in this space. Poly Med won cases against B Braun in India and Germany and Malaysia but lost in Spain. They are planning to tie up with major OEMs and contract manufacture for them. No major plans to foray on its own due to huge costs involved.

Safety IV Cannuale sells at Rs. 18/- while IV Cannuale sells at Rs. 6/- even though it costs only Rs.0.5/- for safety. Currently, Poly Med sells IV Cannuale majorly and Safety IV Cannuale only in some geographies.

Has 3 plants – Faridabad, Jaipur and Haridwar. No expansions possible in the existing Faridabad and Haridwar plants. Jaipur SEZ plant to be operational by March 2014. They have got new land in HSIDC, Faridabad. Capital expenditure of Jaipur SEZ – 38 cr (21 cr loan, 17 cr internal accruals). Investing in Haridwar plant to focus more on domestic market. In FY14, domestic market contributed only 50-60 cr. Rest from exports. Got USFDA approval for its Faridabad plant in Dec 2010.

R&D as a % of sales:

They have increased R&D spend as a % of sales from the past 3 years.












a) Increase in RM costs (crude oil proxy)

b) Exchange rate fluctuations (although, it’s a net exporter)

c) Changing import duty structures (although, off late, govt. has framed favorable policies towards medical and life saving devices)

d) Medical devices heavily regulated (nature of business)

Related Party Transactions and Compensation:

They score pretty high on related party transactions and compensation as a % of sales.

Series of related party transactions with Vitromed healthcare

VitroMed txns






15 cr

11 cr

8 cr

8 cr


21.5 cr

15 cr

13 cr

10 cr

% of PolyMed Sales





MD & ED’s compensation





MD&ED’s comp

3.5 cr

3.1 cr

2.17 cr

1.73 cr

Sales of PolyMed

252 cr

209 cr

170 cr

136 cr

PAT of PolyMed

24 cr

19.2 cr

21.7 cr

16.4 cr

% of Sales





% of PAT





Valuation and Investment theme:

Polymed looks like a 20-25% compounding story with a fairly high probability from these levels. FY13 250 cr sales, 24 cr profit. FY14E 300-310 cr sales, 40 cr profit.

Next 3 years, even if sales double (and assuming NPMs would remain at 12-13% – op. leverage would be set off by increased depreciation of Jaipur SEZ) implies 72 cr profit. Assigning a 20 multiple leads us to 1400 cr marketcap. Current marketcap 750 cr. Implies a 25% CAGR from current levels

Jaipur SEZ spend is about 38 cr and expected sales is about 100-120 cr (2.5-3x asset turnover). If some OEM comes along and if Jaipur SEZ can deliver full demand, sales can double in 2 yrs, and the CAGR would jump to 40%.

Management compensation seems extremely high. Related party txn with Vitromed also needs to be monitored.

However, there is a long ramp for Poly Medicure to grow at 20-25% CAGR. Medical disposable business is an evergreen huge business (unless, there is suddenly a replacement of IV Cannuale with some other tech.) And FY18-19, Poly Med can start selling Safety IV Cannuale anywhere in the world (Braun’s patent expires). Safety IV cannuale is 3-4 times more expensive than IV Cannuale. Think about the impact on revenues and margins.

Disclaimer: This is not a recommendation to buy/sell. This post is only for educational purposes. Please do your own diligence before buying/selling Poly Medicure


, , ,


Stock Analysis: Sabero Organics

I had researched on Sabero Organics about a month back but was too lazy to update on the blog. Thought would rectify it in the new year 🙂

I have not yet invested in the stock. Still reading and researching. Right now, the opportunity costs of investing are pretty high.


Sabero Organics – manufactures agro-chemicals – fungicides, herbicides and insecticides. Sabero is a leading manufacturer of generic products in the agro-chemical space.

Investing theme is broadly – i) patents of major patented agro-chemical products will expire in 2014 ii) Due to increasing environmental concerns and consolidation in China (along with appreciation of yuan), there is a significant possibility of lower production from the Chinese along with better price from India iii) Significant operating leverage and synergies that can be achieved by the Coromandel group.

Their major products in each of the segments are:

1) Herbicide – Glyphosate

2) Fungicide – Mancozeb (registered in the first country in Europe (France) recently); potential of Mancozeb worldwide is $500M; current share is 10-11%; aspiration to take to 20%; it contributes 35-40% of Sabero’s sales (while other core products such as Acephate, Monocrotophos, Glyphosate each contribute 15 per cent to the total sales respectively with the balance 15 per cent coming from Chloropyriphos and others intermediates.)

3) Insecticides – Monochrotophos (main competitor: United Phosphorous)

Share of revenue of Fungicide:Insecticide:Herbicide is 40:40:20

They have subsidiaries in Australia, Europe, Brazil and Argentina.

2009 – 10 AR

Customers of Sabero Organics:

a) 30% of business from MNCs

b) 40% of business from domestic and international B2B

c) 30% of business from dealer distribution network

Sabero is setting up a plant in Dahej SEZ at a cost of Rs. 55 cr. Potential sales of 2-3 times investment. Funded from $9M in ECB debt and rest from internal accruals.

Increased capacity of Chloropyriphos by 50% by Sep 2010.

2010 – 11 AR

2 plants shutdown primarily due to project executions and EMS (environmental) objections

Started supplying to Brazil. Got technical registration for Mancozeb (Brazil is the 2nd largest customer after US in agro-chemicals)

Dahej plant will manufacture synthetic pyrethroids, which have a potential market size of $600M-$700M

Main RMs of Sabero – Ethylenediamine (suppliers are Akzo Nobel, Huntsman and BASF) and Phosphorous, Acetic Anhydride (main supplier Celanese)

Mancozeb plant working at 60% capacity

Supply to Europe has not begun as data protection gets over in June 2011 (Update: In 2013 AR, they do indicate they have registered in France)

40% marketshare in Monochrotophos, rest 60% with United Phosphorous (Cheminova exited the business, leading to a duopoly here)

The joint venture to co-venture partner Markan is under arbitration (Update: In 2012 AR, they have resolved it, taking a hit of approx. 2cr)

2011 – 12 AR

Coromandel (and its subsidiary Parry Chemicals) take 74.57% ownership; Sabero will contribute only 5% of Coromandel’s revenue.

There was a PIL (public interest litigation) filed against the company. Considerable investments were done in environmental management systesm and processes. April 2011 – they were manufacturing 0%; Dec 2011 – their capacity was ramped up to 75%

Manufacture of formulations has begun in Dahej in March 2012

Case with Brazilian company settled

Propineb, with a market potential of $150M – commercialization will begin next year

There has been a sharp fall in the number of Glyphosate herbicide manufacturers, and there can be a 30% reduction in capacity due to consolidation in China in the next 3-5 yrs

Power, fuel and utilities costs shot up to 13.6% vs 7% last year

RM costs also rose sharply

Domestic scale up didn’t happen properly because of availability of products (due to constrained capacity) and erratic monsoons

2012 – 13 AR

Many agro-chemicals going off-patent and due to GM seeds, there has been diversion of R&D funds from agrochemicals to GM seeds

Propineb has been launched (worldwide market of $110M)

Current status of registrations: 296 registrations on 16 products in over 54 countries (183 unique proudcts/country combo)

There has been a 40% increase in trade payables and 100% increase in trade receivables, while sales have grown by only 44%. The massive increase in trade receivables vis-à-vis sales is shown up as negative operating cashflow (-19cr) for the first time. (Are they pushing products on lenient terms then?)

There is absolutely no mention of the status of the Dahej plant.

There are planning to do some capital investment in utilities (drawing board stage), and are targeting EBITDA margins from current 10% to 15%. They can potentially do a 1000 cr turnover in FY15.






































Net Fixed Assets






Fixed Asset Turnover



















H1 FY14 PAT is 26 cr. Given H1 and H2 are similar for Sabero, FY14 PAT would be 52 cr. (There would be no tax impact this year because 61 cr is carried forward from FY12. 7.7 cr has been set off. This 52 cr can also be set off against 61 cr). Tax impact would be 30% from FY15 (unless we know further status of Dahej in which case, it may be a bit lower).

PAT 52 cr. Mkt cap – 492 cr. P/E of 9.5 (Even EV/EBIT (since Sabero has debt) is about 9.5). What would be a fair valuation for such a company?

For FY15, assume best case scenario:

1000 cr turnover, 15% EBITDA margins would imply 150 cr EBITDA. 30 cr interest deduction. 120 cr EBT. 30% tax – PAT would be 84 cr. On a similar 10x multiple, we are looking at 70% upsides from here.

On a realistic basis, 1000 cr turnover, 10% EBITDA, would lead to 50-55 cr of PAT. There is no growth between FY14 and FY15 in PAT (due to full taxation in 2015). Beyond that, there are too many variables.

Of course, increased demand for Mancozeb from Europe (if France is done, other countries can’t be far behind) may further provide tailwinds.


The major risk I see here is any PIL would lead to further pullbacks as production might be stopped. Also, GPCB has given time till mid-Feb to clear out some backlogs on environmental concerns. I think getting a clearance would be paramount (although, given Coromandel’s pedigree, don’t see much of a risk here).

Another major risk is obviously steep increase in RM prices. This is a risk on balance – as production of end product from other countries is dwindling, and as is the manufacture of phosphorous from China. We may get into a higher pricing scenario, but so would our RM cost increase. Net-net, I don’t see an asymmetric benefit of China rampdown.

Another risk is inter-party related transactions – say, if the Dahej plant production is being restructured to be a backward integrated supplier for Coromandel-Liberty merger, then the upside is going to be very limited. We need to be careful of the pricing structure here. Of course, delisting is another risk (will lead to re-investment risk)

Disclosure: I have not invested as of yet. This is not a buy/sell recommendation. This post is only for learning and posterity. Please do your own due diligence before investing

, ,


Indian Companies list in Forbes Asia’s Best under a Billion 2010

I was researching on a stock and I landed up on this link, which points to Forbes Asia’s Best under a Billion in Sep 2010. I am really late to the party I guess. I have compiled the list of all Indian companies on that list here. And as every foolish investor does all the time, I have tried to put my insightful insights (!) against each stock. I am also taking the risk of sharing my immense wisdom with you all. Get ready to lose your money by investing based on my comments.


S.No Company Industry My Comments
1 Allied Digital Services Software & Services Some auditor raid recently. In the Remote Infrastructure space(RIMS). Promising, but be careful.
2 Amara Raja Batteries Capital Goods Available cheaper than its competitor Exide with P/E of 11 vis-à-vis P/E of 20 for Exide. Promoter issue though. Expanding inverter market might push up revenues
3 Ashiana Housing Construction Promising player. Macro interest scenario doesn’t help though. Pretty positive on this stock.
4 Banco Products (India) Capital Goods No idea about this stock. But in general, Capital Goods industry would require capital to grow. And with capital requirement comes debt. A B2B company in the Capital Goods industry in general cannot generate above average returns unless bought into a 2008 kind of market.
5 Bliss GVS Pharma Drugs & Biotechnology I don’t understand Pharma sector currently. But whatever I hear about Pharma, this one seems pretty high on the list along with Ajanta Pharma
6 Compact Disc (India) Media I’d stay away from this stock even if it gets dead cheap.
7 Core Projects & Technologies Software & Services No idea about this stock.
8 Deep Industries Oil & Gas Operations No idea about this stock.
9 Dhanuka Agritech Chemicals One of the very promising players in the Agri space. Definitely worth a look in. Inventory days and debtor days seem to be a concern.
10 ELGI Equipments Capital Goods No idea about this stock. The capital goods comment for Banco (above) works here too I guess.
11 Emami Household & Personal Products Very much gung-ho on FMCG. This one looks a tad expensive though at current levels. There are better FMCG stocks out there. Can definitely look into this in case of any major correction.
12 Everonn Education Business Services & Supplies This education sector promise has ruined many an investor till date (remember the Educomp mania?). I haven’t researched into this stock though.
13 Exide Industries Consumer Durables Market leader in Batteries. This one along with Amara Raja seem decent plays.
14 FDC Drugs & Biotechnology No idea about this stock.
15 Glodyne Technoserve Software & Services The Allied Digital Services fiasco has rubbed off on this RIMS space player too. No stock specific data though.
16 GSS America Infotech Software & Services No idea about this stock.
17 Hyderabad Industries Construction This stock along with Visaka are starting to look promising at these price levels. Interestingly poised.
18 ICSA (India) Software & Services I mistook this for ICRA when I first saw this and started digging into numbers. I didn’t like the numbers.
19 Indag Rubber Chemicals The rubber industry is very interestingly poised. Indag along with Balkrishna and Gujarat Reclaim are good bets.
20 Jindal Drilling & Industries Oil & Gas Operations No idea about this stock
21 Jubilant Organosys Drugs & Biotechnology No idea about this stock.
22 Kaveri Seed Food Drink & Tobacco No idea about this stock.
23 KNR Constructions Construction No idea about this stock.
24 Liberty Phosphate Chemicals This is more of a fertilizer play. This one along with Rama Phosphate and Khaitan Chemicals are 3 major players in Single Sulphur Phosphate, a super fertilizer (SSP). SSP (Single Super Phosphate) was almost a dead industry brought back to life by the new Nutrient Based Subsidy (NBS) scheme notified by the Government of India. Dig in further if you are interested
25 Micro Technologies (India) Software & Services No idea about this stock.
26 Navin Fluorine International Chemicals I’d stay away from this stock even if it gets dead cheap.
27 Nitin Fire Protection Industries Conglomerates For some reason, the numbers don’t excite me at all. I am neutral on this.
28 Omnitech Infosolutions Software & Services Good player in the RIMS space. Decent bet.
29 Ponni Sugars (Erode) Food Drink & Tobacco Cyclical industry. I usually stay away from cyclicals. Bajaj Hindusthan, the largest player in this space looks interesting.
30 Ranklin Solutions Software & Services This one appeared on my debt capacity bargain screener. Very small player – difficult to evaluate. No revenue visibility.
31 Sandur Manganese & Iron Ores Materials No idea about this stock.
32 Seamac Construction No idea about this stock.
33 Solar Industries India Chemicals No idea about this stock.
34 Spice Mobility Technology Hardware & Equipment No idea about this stock.
35 Transformers & Rectifiers (India) Capital Goods Good play in the Power space. Again, capital goods sector – no great/fantastic returns. Just steady returns expected.
36 Ushdev International Utilities Seems like a trading play on Steels at first look. I shall pass.
37 Vinati Organics Chemicals Impressive stock. Accumulate on declines
38 Wim Plast Consumer Durables Impressive growth. Good potential. Has run up recently. Accumulate on declines
39 Zydus Wellness Food Drink & Tobacco The stock’s run away. Should deliver steady returns. Keep a watch for declines and accumulate

, , , ,


Stock Analysis: Gandhi Special Tubes (GandhiTube)

Gandhi Special Tubes manufactures and sells automobile components, primarily in India. It offers a range of small and big diameter seamless and welded tubes along with tubular components, such as condensers, compressor parts, fuel injection tube assemblies, and hydraulic tubes. It was incorporated in 1985 and set up its first plant at Halol, Gujarat in technical collaboration with German manufacturer Benteler. Benteler have supplied most of the critical machines and were involved in installation and commissioning of the plant and training personnel in India as well as Germany.

GSTL produces special tubes of small diameter ranging from 3mm to 75mm. These special tubes are used across automobile, refrigeration and engineering industries. GSTL have also started manufacturing cold formed tube nuts for Fuel Injection Tube Assemblies as well as Hydraulic Tube Assemblies. This is a pioneering effort in India as previously tube nuts were being manufactured by machining. GSTL currently derives 80% of its revenues from the automobile sector and the rest from refrigeration and engineering.Apart from its manufacturing business the company also has five windmills with a total installed capacity of 5.35 MW, providing part of the company’s energy supply. The three windmills located in Gujarat are for captive consumption whereas the two in Maharashtra are for commercial purposes. Gandhi Special Tubes Limited also exports its products to customers in Germany, the United Kingdom, and the south east Asian countries.

Company is debt free and has invested surplus cash in capacity expansion & wind mills for captive power consumption. It has a marquee list of clients which include L&T, Maruti Udyog, Ashok Leyland, M&M, BEML, Voltas, Electrolux and Kirloskar among many others.


CMP: Rs. 123.55

Market Cap: 181.62 Cr

Face Value: Rs. 5

Promoter’s Shareholding: 73%

Book Value: Rs. 69

P/E: 6.95

P/B: 1.77

One of Walter Schloss criteria -> Promoter’s Shareholding > 50% is satisfied.

Looking at the basic financial ratios –

Variable                       Current            Industry Median

Net Profit Margin           33.56                1.84

Operating Profit Margin 41.34                5.93

Asset Turnover             0.74                  1.52

Return on Assets          24.95                3.15

Return on Equity           24.95                7.94

Debt to Equity               0.00                  0.96

Return on CE                 35.90                9.73

Interest Coverage         728.80              1.70

Just on basis of ratios, we can derive that –

Superior ROCE, Superior RoE, No debt, Terrific interest coverage coupled with reasonable P/E and P/B make it an attractive stock to be in.

Let’s look at the history of management’s performance, rather than a single snapshot (just to ensure we are not under the influence of some accounting shenanigans or one time fad market).

Variable                       FY06    FY07    FY08    FY09    FY10

Net Profit Margin           29.75    21.41    24.74    28.36    33.56

Operating Profit Margin 35.69    35.53    37.80    38.84    41.34

Return on Assets           32.14    21.64    25.56    18.73    24.95

Return on Equity            32.88    21.96    25.76    18.79    24.95

Capital Employed           50.22    59.46    73.72    85.07    101.51

Return on CE                 36.92    32.64    36.54    27.35    35.90

Free Cash Flow to Sales  –           3.09      3.15      31.31    27.44

Dividend Payout             18.22    22.84    19.48    23.10    29.02

Based on the above table, we can derive that

– GSTL has consistently maintained high NPMs and OPMs over the past 5 years (signifying moat)

– GSTL has had superior return ratios all throughout for the past 5 years (in fact, I checked the results from FY2002 and the results don’t differ much)

– The cream, would be a very good dividend payout, consistently increasing year on year. Current dividend yield is 4%.

– Margin of safety: It has cash of almost Rs. 24 per share. That’s almost 20% of the current share price.

Apart from all these ratios and parameters, on an absolute basis –

1) The Book value for GSTL has increased at a CAGR of 20% over the past 5 years. (adjusting for stock split 1:2 in 2008 )

2) The Net Sales have had a CAGR of 11% and PAT has had a CAGR of 20% over the past 5 years.

All the above factors indicate that the business has a moat, a capable management which can deliver results on a consistent basis (atleast, for the past 8 years that I have read the results) and has paid dividends consistently which gives us a margin of safety.


1) The cost of Raw materials is more than 30% of the total cost incurred. Any increase in the prices of raw materials (steel, for example) would put pressure on margins.

2) The cost of power also eats into profit. However, the captive power consumption should reduce power costs to a large extent in the coming quarters.

3) Sales have been stagnant for the past 2 years.

4) Illiquid stock. Garnering even 400 shares would be slightly challenging.

5) Foray into commercial power generation from Maharashtra windmills is still something I am getting my head around with. Is this diworsefication or a temporary arrangement before they consumer the entire power captively?


1) The consumer story is in a stage of rapid growth in India. GSTL is well placed to supply tubes to various consumer durable companies.

2) With the foray into the Engineering segment, sales might increase in the near future.


GSTL is a virtual monopoly in this industry segment, consistently generating high ROCE and Free cash flow. Its dividend yield of 4% along with the safety of Rs. 24/share cash makes it an attractive stock. I would term GSTL to be a value buy at these levels (and probably accumulate more on declines). The stock is undervalued to say the least and will give good returns if it keeps up with the performance of previous years.

Disclosure: I have initiated a small position in the stock.

, ,

1 Comment